Table 1.
Baseline characteristics of prostate cancer cases and controls1 in the Prostate Cancer Prevention Trial by race
| Characteristics | Caucasian (n=2156) | African American (n=177) | ||
|---|---|---|---|---|
| Case | Control | Case | Control | |
| Number | 1081 | 1075 | 47 | 130 |
| Age, mean years (range) | 63.5 (55–82) | 64.0 (55–84) | 61.9 (55–77) | 61.7 (55–77) |
| Finasteride Treatment Arm, n (%) | 446 (41.3) | 419 (39.0) | 20 (42.6) | 81 (62.3) |
| Family History of prostate cancer, n (%) | 235 (21.7) | 244 (22.7) | 7 (14.9) | 24 (18.5) |
| BMI (kg/m2), mean (range) | 27.3 (19–52) | 27.6 (19–46) | 29.4 (21–47) | 28.5 (17–42) |
| Gleason ≥7, n (% of all cases) | 269 (24.9) | N/A | 17 (36.2) | N/A |
1.
Nested case control selection frequency matched on age, first degree family history of prostate cancer and treatment arm with oversampling for eligible African-Americans.